Results of the 2nd scientific workshop of the ECCO (IV): Therapeutic strategies to enhance intestinal healing in inflammatory bowel disease

Journal of Crohn's and Colitis

Volumn 6, Issue 4, 2012, Pages 492-502

  Armuzzi, Alessandro ^a   Van Assche, Gert ^b   Reinisch, Walter ^c   de Chambrun, Guillaume Pineton ^d   Griffiths, Anne ^e   Sladek, Malgorzata ^f   Preiss, Jan C ^g   Lukas, Milan ^h   D'Haens, Geert ⁱ  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIV LILLE   (France)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h CHARLES UNIVERSITY   (Czech Republic)

ⁱ UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Crohn's disease; Inflammatory bowel disease; Mucosa healing; Treatment; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BUDESONIDE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CORTISONE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; NATALIZUMAB; PLACEBO; PREDNISOLONE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

COLON RESECTION; COLONOSCOPY; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE SEVERITY; DRUG MEGADOSE; ENTERIC FEEDING; FOLLOW UP; HEALING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE HEALING; MONOTHERAPY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENCE RISK; REMISSION; REVIEW; SIGMOIDOSCOPY; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; ENDOSCOPY, GASTROINTESTINAL; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MESALAMINE; METHOTREXATE; TREATMENT OUTCOME;

EID: 84860130277     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2011.12.016     Document Type: Review

References (75)

1. Pariente B., Cosnes J., Danese S., Sandborn W.J., Lewin M., Fletcher J.G., et al. Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis 2011, 17:1415-1422.
2. Frøslie K.F., Jahnsen J., Moum B.A., Vatn M.H., IBSEN Group Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007, 133:412-422.
3. Solberg I.C., Lygren I., Jahnsen J., Vatn M., Moum B. Mucosal healing after initial treatment may be a prognostic marker for long-term outcome in inflammatory bowel disease. Gut 2008, 57(Suppl. 2):A-15.
4. Baert F., Moortgat L., Van Assche G., Caenepeel P., Vergauwe P., De Vos M., et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010, 138:463-468.
5. D'Haens G.R., Noman M., Baert F., Hiele M., Van Assche G., Daperno M., et al. Endoscopic healing after infliximab treatment for Crohn's disease provides a longer time to relapse. Gastroenterology 2002, 122(Suppl. 1):A100.
6. Rutgeerts P., Diamond R.H., Bala M., Olson A., Lichtenstein G.R., Bao W., et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006, 63:433-442.
7. Schnitzler F., Fidder H., Ferrante M., Noman M., Arijs I., Van Assche G., et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009, 15:1295-1301.
8. Colombel J.F., Rutgeerts P.J., Sandborn W.J., Camez A.A., Pollack P.F., Chen N., et al. Adalimumab treatment results in deep remission for patients with moderate to severe ileocolonic Crohn's disease: results from EXTEND. Gastroenterology 2010, 138(Suppl. 1):S518.
9. Wright R., Truelove S.R. Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets. Am J Dig Dis 1966, 11:847-857.
10. Meucci G., Fasoli R., Saibeni S., Valpiani D., Gullotta R., Colombo E., et al. Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: preliminary results of a prospective, multicenter study. Gastroenterology 2006, 130(Suppl. 2):A197.
11. Kamm M.A., Lichtenstein G.R., Sandborn W.J., Schreiber S., Lees K., Barrett K., et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008, 57:893-902.
12. Ferrante M., Vermeire S., Fidder H., Schnitzler F., Noman M., Van Assche G., et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis 2008, 2:219-225.
13. Colombel J.F., Rutgeerts P., Reinisch W., Esser D., Wang Y., Lang Y., et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011, 141:1194-1201.
14. Sandborn W.J., Feagan B.G., Hanauer S.B., Lochs H., Löfberg R., Modigliani R., et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002, 122:512-530.
15. D'Haens G., Sandborn W.J., Feagan B.G., Geboes K., Hanauer S.B., Irvine E.J., et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007, 132:763-786.
16. Mary J.Y., Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989, 30:983-989.
17. Daperno M., D'Haens G., Van Assche G., Baert F., Bulois P., Maunoury V., et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004, 60:505-512.
18. Rutgeerts P., Geboes K., Vantrappen G., Beyls J., Kerremans R., Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990, 99:956-963.
19. Schroeder K.W., Tremaine W.J., Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987, 317:1625-1629.
20. Baron J.H., Connell A.M., Lennard-Jones J.E. Variation between observers in describing mucosal appearances in proctocolitis. BMJ 1964, 1:89-92.
21. Sands B.E., Abreu M.T., Ferry G.D., Griffiths A.M., Hanauer S.B., Isaacs K.L., et al. Design issues and outcomes in IBD clinical trials. Inflamm Bowel Dis 2005, 11(Suppl. 1):S22-S28.
22. Pineton de Chambrun G., Peyrin-Biroulet L., Lémann M., Colombel J.F. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010, 7:15-29.
23. Lichtenstein G.R., Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2010, 16:338-346.
24. Targan S.R., Hanauer S.B., van Deventer S.J., Mayer L., Present D.H., Braakman T., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997, 337:1029-1035.
25. Colombel J.F., Rutgeerts P., Reinisch W., Mantzaris G.J., Kornbluth A., Rachmilewitz D., Sonic Study Group, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-1395.
26. Rutgeerts P., D'Haens G.R., Van Assche G.A., Sandborn W.J., Wolf D.C., Colombel J.F., et al. Adalimumab induces and maintains mucosal healing in patients with moderate to severe ileocolonic Crohn's disease - first results of the extend trial. Gastroenterology 2009, 136(Suppl. 1):A116.
27. Sandborn W.J., Kamm M.A., Lichtenstein G.R., Lyne A., Butler T., Joseph R.E. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 2007, 26:205-215.
28. Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., Olson A., Johanns J., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
29. Reinisch W., Sandborn W.J., Hommes D.W., D'Haens G., Hanauer S., Schreiber S., et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011, 60:780-787.
30. Panaccione R., Ghosh S., Middleton S., Marquez J.R., Khalif I., Flint L., et al. Infliximab, azathioprine, or infliximab+azathioprine for treatment of moderate to severe ulcerative colitis. Gastroenterology 2011, 140(Suppl. 1):S134.
31. Simren M., Axelsson J., Gillberg R., Abrahamsson H., Svedlund J., Björnsson E.S. Quality of life in inflammatory bowel disease in remission: the impact on IBS-like symptoms an associated psychological factors. Am J Gastroenterol 2002, 97:389-396.
32. Louis E., Mary J.Y., Vernier-Massouille G., Grimaud J.C., Bouhnik Y., Laharie D., et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012, 142:63-70.
33. Landi B., Anh T.N., Cortot A., Soule J.C., Rene E., Gendre J.P., et al. Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1992, 102:1647-1653.
34. Present D.H. 6-Mercaptopurine and other immunosuppressive agents in the treatment of Crohn's disease and ulcerative colitis. Gastroenterol Clin North Am 1989, 18:57-71.
35. D'Haens G., Geboes K., Ponette E., Penninckx F., Rutgeerts P. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology 1997, 112:1475-1481.
36. D'Haens G., Geboes K., Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc 1999, 50:667-671.
37. Modigliani R., Mary J.Y., Simon J.F., Cortot A., Soule J.C., Gendre J.P., et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990, 98:811-818.
38. Olaison G., Sjödahl R., Tagesson C. Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation. Gut 1990, 31:325-328.
39. Mantzaris G.J., Christidou A., Sfakianakis M., Roussos A., Koilakou S., Petraki K., et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease. Inflamm Bowel Dis 2009, 15:375-382.
40. Lémann M., Mary J.Y., Colombel J.F., Duclos B., Soule J.C., Lerebours E., et al. Groupe D'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 2005, 128:1812-1818.
41. D'Haens G., Baert F., van Assche G., Caenepeel P., Vergauwe P., Tuynman H., et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008, 371:660-667.
42. Reinisch W., Angelberger S., Petritsch W., Shonova O., Lukas M., Bar-Meir S., et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut 2010, 59:752-759.
43. Kozarek R.A., Patterson D.J., Gelfand M.D., Botoman V.A., Ball T.J., Wilske K.R. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989, 110:353-356.
44. Feagan B.G., Rochon J., Fedorak R.N., Irvine E.J., Wild G., Sutherland L., et al. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995, 332:292-297.
45. Feagan B.G., Fedorak R.N., Irvine E.J., Wild G., Sutherland L., Steinhart A.H., et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. N Engl J Med 2000, 342:1627-1632.
46. Laharie D., Reffet A., Belleannée G., Chabrun E., Subtil C., Razaire S., et al. Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab. Aliment Pharmacol Ther 2011, 33:714-721.
47. D'Haens G., van Deventer S., van Hogezand R., Chalmers D., Kothe C., Baert F., et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999, 116:1029-1034.
48. Rutgeerts P., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004, 126:402-413.
49. Hébuterne X., Colombel J., Bouhnik Y., Dewit O., Dupas J., Mross M., et al. Endoscopic improvement in patients with active Crohn's disease treated with certolizumab pegol: first results of the MUSIC trial. Gut 2008, 57(Suppl. 2):A15.
50. Sandborn W.J., Colombel J.F., Enns R., Feagan B.G., Hanauer S.B., Lawrance I.C., et al. International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005, 353:1912-1925.
51. Rutgeerts P., Allison M.C., Cortot A., D'Haens G., Dahlemp J.F., Hebuteme X., et al. Effects of natalizumab on gut healing in a phase 3 study of active Crohn's disease therapy (ENACT-1). Gastroenterology 2004, 126(Suppl. 2):A-208.
52. Zachos M., Tondeur M., Griffiths A.M. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2007, 1:CD000542.
53. Akobeng A.K., Thomas A.G. Enteral nutrition for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2007, 3:CD005984.
54. Borrelli O., Cordischi L., Cirulli M., Paganelli M., Labalestra V., Uccini S., et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol 2006, 4:744-753.
55. Riley S.A., Mani V., Goodman M.J., Dutt S., Herd M.E. Microscopic activity in ulcerative colitis: what does it mean?. Gut 1991, 32:174-178.
56. Courtney M.G., Nunes D.P., Bergin C.F., et al. Colonoscopic appearance in remission predicts relapse of ulcerative colitis. Gastroenterology 1991, 100:A205.
57. Campieri M., Lanfranchi G.A., Bazzocchi G., Brignola C., Sarti F., Franzin G., et al. Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet 1981, 2(8241):270-271.
58. Truelove S.C., Witts L.J. Cortisone in ulcerative colitis. Final report on a therapeutic trial. BMJ 1955, 2:1041-1048.
59. Ardizzone S., Maconi G., Russo A., Imbesi V., Colombo E., Bianchi-Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006, 55:47-53.
60. Paoluzi O.A., Pica R., Marcheggiano A., Crispino P., Iacopini F., Iannoni C., et al. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment Pharmacol Ther 2002, 16:1751-1759.
61. Sandborn W.J., Van Assche G., Reinisch W., Colombel J., D'Haens G., Wolf D.C., et al. Induction and maintenance of clinical remission by adalimumab in patients with moderate-to-severe ulcerative colitis. J Crohns Colitis 2011, 5(1):P136.
62. Feagan B.G., Greenberg G.R., Wild G., Fedorak R.N., Paré P., McDonald J.W., et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005, 352:2499-2507.
63. Markowitz J., Grancher K., Kohn N., Lesser M., Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000, 119:895-902.
64. Candy S., Wright J., Gerber M., Adams G., Gerig M., Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995, 37:674-678.
65. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
66. Hyams J., Crandall W., Kugathasan S., Griffiths A., Olson A., Johanns J., et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007, 132:863-873.
67. Colombel J.F., Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Panaccione R., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
68. Hyams J., Griffiths A.M., Markowitz J., Baldassano R., Faubion W., Colletti R., et al. Induction and maintenance adalimumab therapy for the treatment of moderate to severe Crohn's disease in children. J Crohn's Colitis 2011, 5:S5-S6.
69. Colombel J.F., Schreiber S., Rutgeerts P.J., Sandborn W.J., Yang M., Lomax K.G., et al. Effect of disease duration on "deep remission": results from the Extend trial. Gut 2010, 59(Suppl. III):A188.
70. Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Allaart C.F., van Zeben D., Kerstens P.J., Hazes J.M., et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005, 52:3381-3390.
71. Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Allaart C.F., van Zeben D., Kerstens P.J., Hazes J.M., et al. Comparison of treatment strategies in early rheumatoid arthritis a randomized trial. Ann Intern Med 2007, 146:406-415.
72. Regueiro M., Loftus E.V., Steinhart A.H., Cohen R.D. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis 2006, 12:979-994.
73. Marteau P., Probert C.S., Lindgren S., Gassul M., Tan T.G., Dignass A., et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005, 54:960-965.
74. Treton X., Bouhnik Y., Mary J.Y., Colombel J.F., Duclos B., Soule J.C., et al. Groupe D'Etude Thérapeutique Des Affections Inflammatoires Du Tube Digestif (GETAID). Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol 2009, 7:80-85.
75. Cassinotti A., Actis G.C., Duca P., Massari A., Colombo E., Gai E., et al. Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal. Am J Gastroenterol 2009, 104:2760-2767.